Photo of Aria F. Olumi, MD

Aria F. Olumi, MD

  • Director, Urology Research
  • Co-Director, GU Oncology Clinical Program


Accepting New Patients


Aria F. Olumi, MD, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.



Centers & Specialties

Cancer Center

Clinical Interests
  • Prostate cancer
  • Kidney cancer
  • Bladder cancer
  • Testicular, penile and genito-urinary cancers
  • Laparoscopic surgery, Robotic surgery, Open surgery
  • Minimally invasive laser surgery for enlarged prostates
  • Brachytherapy (radioactive seeds) for prostate cancer
Medical Education
  • MD, University of Southern California Keck School of Medicine
  • Residency, Brigham and Women's Hospital
  • Fellowship, University of California, San Francisco
Board Certifications
  • Urology
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile

Research & Publications

Research Summary
Dr. Olumi's laboratroy focuses on mechanisms of inducing death in cancer cells.  The laboratory has been investigating the drug, TRAIL, that induces death in cancer cells, but not normal cells, therefore, patients experience minimal side effects from the drug.  Since some cancer cells develop resistance to the drug, TRAIL, the laboratory is investigating molecular mechanisms to convert resistant cancer cells to become sensitive.  The Olumi lab has identified two novel pathways of regulating resistant cancer cells (c-Fos and FBXL10).  The research can lead to improvement of currently available cancer therapies and development of new cancer therapy agents.

View my most recent publications at PubMed

Zhang X, Zhang L, Yang H, Huang, X, Otu H, Liberman T, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a pro-apoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Research, 2007, 67: 9425-34.

Li W, Wu CH, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. American Journal of Pathology, 2007, Oct;171:1189-98.

Zhang X*, Huang X*, Olumi AF (*contributed equally). Repression of NF-kB and Activation of AP-1 Enhance Apoptosis in Prostate Cancer Cells. International Journal of Cancer. 2009;124(8):1980-9.

Olumi AF, DeWolf WC. The Hybrid of Basic Science and Clinical Training for the Urologic Oncologist: Necessity or Waste? Urologic Oncology. 2009;27:205-7.

Edit Profile

News & Events

  • Prostate Health Month

    September is Prostate Health Month. MGH urologists discuss the prostate, its impact on men's health and offer advice on PSA screenings.



Mass General Urology Associates
15 Parkman St
Boston MA, 02114-3117
Phone 1: 617-643-0237
Fax: 617-643-4019

Edit Profile

Back to Top